Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-tocopheryloxyacetic Acid (α-TEA) in Advanced Cancer
NCT02192346Phase 1Completed
- Start
- Aug 2014
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of alpha-tocopheryloxyacetic acid in metastatic carcinoma, sarcoma and lymphoma (9 arms). Primary endpoint: Number of Participants with Adverse Events at 28 Days. Started Aug 2014; status: completed.
02
Drugs
alpha-tocopheryloxyacetic acid
03
Conditions
metastatic carcinomasarcomalymphoma
Beyond the preview
Go deeper on NCT02192346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02192346.